|
| 36762930 | Mixed Origins: HIV gp120-Specific Memory Develops from Pre-Existing Memory and Naive B Cells Following Vaccination in Humans. | AIDS Res Hum Retroviruses | 2023 |
| 37795976 | Protein dose-sparing effect of AS01B adjuvant in a randomized preventive HIV vaccine trial of ALVAC-HIV (vCP2438) and adjuvanted bivalent subtype C gp120. | J Infect Dis | 2023 |
| 37698412 | Daily fosfomycin versus levofloxacin for complicated urinary tract infections. | mBio | 2023 |
| 34117753 | Time to Viral Rebound After Interruption of Modern Antiretroviral Therapies. | Clin Infect Dis | 2022 |
| 36537546 | Exploring a community's understanding of HIV vaccineâ¿¿induced seropositivity in a South African research setting. | S Afr Med J | 2022 |
| 36179551 | Baseline host determinants of robust human HIV-1 vaccine-induced immune responses: A meta-analysis of 26 vaccine regimens. | EBioMedicine | 2022 |
| 35090638 | Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: interim findings from a phase 2, randomised, dose-finding, multicentre study. | Lancet Infect Dis | 2022 |
| 34229888 | AIDSVAX protein boost improves breadth and magnitude of vaccine-induced HIV-1 envelope-specific responses after a 7-year rest period. | Vaccine | 2021 |
| 33887209 | Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1-2, dose-ranging study. | Lancet Infect Dis | 2021 |
| 34587382 | Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine. | N Engl J Med | 2021 |
| 34843602 | Sequence and vector shapes vaccine induced antibody effector functions in HIV vaccine trials. | PLoS Pathog | 2021 |
| 34745131 | CD4+ T Cells Are Dispensable for Induction of Broad Heterologous HIV Neutralizing Antibodies in Rhesus Macaques. | Front Immunol | 2021 |
| 34185068 | Assessment of Coronary Artery Disease With Computed Tomography Angiography and Inflammatory and Immune Activation Biomarkers Among Adults With HIV Eligible for Primary Cardiovascular Prevention. | JAMA Netw Open | 2021 |
| 31131858 | Antiretroviral Therapy Reduces T-cell Activation and Immune Exhaustion Markers in Human Immunodeficiency Virus Controllers. | Clin Infect Dis | 2020 |
| 31996422 | Effect of HIV Envelope Vaccination on the Subsequent Antibody Response to HIV Infection. | mSphere | 2020 |
| 33297341 | Intramuscular and Intradermal Electroporation of HIV-1 PENNVAX-GP<sup>®</sup> DNA Vaccine and IL-12 Is Safe, Tolerable, Acceptable in Healthy Adults. | Vaccines (Basel) | 2020 |
| 32747654 | Impact of vaccine type on HIV-1 vaccine elicited antibody durability and B cell gene signature. | Sci Rep | 2020 |
| 32577626 | Persistence of HIV-1 Env-Specific Plasmablast Lineages in Plasma Cells after Vaccination in Humans. | Cell Rep Med | 2020 |
| 32680773 | Long-term mucosal T cell activation and homing phenotypes in recipients of an Ad5-vectored HIV vaccine. | Vaccine | 2020 |
| 32123636 | House Ball Community Leaders' Perceptions of HIV and HIV Vaccine Research. | Int J MCH AIDS | 2020 |
| 32496516 | Maintenance of Viral Suppression in Human Immunodeficiency Virus Controllers Despite Waning T-Cell Responses During Antiretroviral Therapy. | J Infect Dis | 2020 |
| 30862743 | Broad and Protective Influenza B Virus Neuraminidase Antibodies in Humans after Vaccination and their Clonal Persistence as Plasma Cells. | mBio | 2019 |
| 31434737 | Fc Gamma Receptor Polymorphisms Modulated the Vaccine Effect on HIV-1 Risk in the HVTN 505 HIV Vaccine Trial. | J Virol | 2019 |
| 31566579 | DNA priming and gp120 boosting induces HIV-specific antibodies in a randomized clinical trial. | J Clin Invest | 2019 |
| 31444712 | Reducing the African American HIV Disease Burden in the Deep South: Addressing the Role of Faith and Spirituality. | AIDS Behav | 2019 |
| 30926296 | IL-33 enhances the kinetics and quality of the antibody response to a DNA and protein-based HIV-1 Env vaccine. | Vaccine | 2019 |
| 29325070 | Modification of the Association Between T-Cell Immune Responses and Human Immunodeficiency Virus Type 1 Infection Risk by Vaccine-Induced Antibody Responses in the HVTN 505 Trial. | J Infect Dis | 2018 |
| 30427829 | First-in-human randomized controlled trial of an oral, replicating adenovirus 26 vector vaccine for HIV-1. | PLoS One | 2018 |
| 30364428 | Randomized Clinical Trial to Assess the Impact of the Broadly Neutralizing HIV-1 Monoclonal Antibody VRC01 on HIV-1 Persistence in Individuals on Effective ART. | Open Forum Infect Dis | 2018 |
| 29590326 | Safety and Immunogenicity of Zoster Vaccine Live in Human Immunodeficiency Virus-Infected Adults With CD4+ Cell Counts >200 Cells/mL Virologically Suppressed on Antiretroviral Therapy. | Clin Infect Dis | 2018 |
| 29531320 | A Highly Potent and Broadly Neutralizing H1 Influenza-Specific Human Monoclonal Antibody. | Sci Rep | 2018 |
| 29089933 | Curaxin CBL0100 Blocks HIV-1 Replication and Reactivation through Inhibition of Viral Transcriptional Elongation. | Front Microbiol | 2017 |
| 28199679 | Higher T-Cell Responses Induced by DNA/rAd5 HIV-1 Preventive Vaccine Are Associated With Lower HIV-1 Infection Risk in an Efficacy Trial. | J Infect Dis | 2017 |
| 28222180 | Pre-existing neutralizing antibody mitigates B cell dysregulation and enhances the Env-specific antibody response in SHIV-infected rhesus macaques. | PLoS One | 2017 |
| 27379802 | Humoral Dysregulation Associated with Increased Systemic Inflammation among Injection Heroin Users. | PLoS One | 2016 |
| 26475930 | Vaccination With Heterologous HIV-1 Envelope Sequences and Heterologous Adenovirus Vectors Increases T-Cell Responses to Conserved Regions: HVTN 083. | J Infect Dis | 2016 |
| 27612555 | Increased Steady-State Memory B Cell Subsets Among High-Risk Participants in an HIV Vaccine Trial. | AIDS Res Hum Retroviruses | 2016 |
| 25820067 | Multiple factors affect immunogenicity of DNA plasmid HIV vaccines in human clinical trials. | Vaccine | 2015 |
| 26332672 | Effect of rAd5-Vector HIV-1 Preventive Vaccines on HIV-1 Acquisition: A Participant-Level Meta-Analysis of Randomized Trials. | PLoS One | 2015 |
| 26587311 | Safety and Immunogenicity of a Recombinant Adenovirus Serotype 35-Vectored HIV-1 Vaccine in Adenovirus Serotype 5 Seronegative and Seropositive Individuals. | J AIDS Clin Res | 2015 |
| 26229114 | HIV-1 VACCINES. Diversion of HIV-1 vaccine-induced immunity by gp41-microbiota cross-reactive antibodies. | Science | 2015 |
| 25897603 | Functional and Molecular Characteristics of Novel and Conserved Cross-Clade HIV Envelope Specific Human Monoclonal Antibodies. | Monoclon Antib Immunodiagn Immunother | 2015 |
| 24403557 | Specificity and 6-month durability of immune responses induced by DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles. | J Infect Dis | 2014 |
| 25642120 | Project VOGUE: A partnership for increasing HIV knowledge and HIV vaccine trial awareness among House Ball leaders in Western New York. | J Gay Lesbian Soc Serv | 2014 |
| 25435557 | Capacity building among african american faith leaders to promote HIV prevention and vaccine research. | Prog Community Health Partnersh | 2014 |
| 25253665 | Phase I/II randomized trial of safety and immunogenicity of LIPO-5 alone, ALVAC-HIV (vCP1452) alone, and ALVAC-HIV (vCP1452) prime/LIPO-5 boost in healthy, HIV-1-uninfected adult participants. | Clin Vaccine Immunol | 2014 |
| 24865892 | Theoretical model of critical issues in informed consent in HIV vaccine trials. | AIDS Care | 2014 |
| 24609066 | Broad HIV epitope specificity and viral inhibition induced by multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults. | PLoS One | 2014 |
| 22965693 | Bridging the digital divide in HIV care: a pilot study of an iPod personal health record. | J Int Assoc Provid AIDS Care | 2013 |
| 24386452 | 9G4+ antibodies isolated from HIV-infected patients neutralize HIV-1 and have distinct autoreactivity profiles. | PLoS One | 2013 |